From: The efficacy of low-dose aspirin in pregnancy among women in malaria-endemic countries
Variable | Overall | Malaria Negative | Malaria Positive | Aspirin ā Malaria InteractionĀ p-value | |||
---|---|---|---|---|---|---|---|
n/N (%) | PR (95% CI) | n/N (%) | PR (95% CI) | n/N (%) | PR (95% CI) | ||
Primary Outcome | |||||||
Ā Preterm delivery | |||||||
Ā Ā Aspirin | 83/724 (11) | 0Ā·92 (0Ā·70, 1Ā·22) | 38/445 (9) | 0Ā·89 (0Ā·59, 1Ā·36) | 45/279 (16) | 0Ā·95 (0Ā·66, 1Ā·38) | 0.75 |
Ā Ā Placebo | 90/722 (12) | Ā | 42/439 (10) | Ā | 48/283 (17) | Ā | Ā |
Hypertensive disorders | |||||||
Ā Aspirin | 10/724 (1) | 1Ā·11 (0Ā·45, 2Ā·71) | 8/445 (2) | 0Ā·88 (0Ā·34, 2Ā·25) | 2/279 (1) | 5Ā·07 (0Ā·24, 105Ā·17) | ā |
Ā Placebo | 9/722 (1) | Ā | 9/439 (2) | Ā | 0/283 (0) | Ā | Ā |
Small for gestational age | |||||||
Ā Aspirin | 89/686 (13) | 1Ā·11 (0Ā·84, 1Ā·48) | 58/421 (14) | 1Ā·21 (0Ā·84, 1Ā·73) | 31/265 (12) | 0Ā·97 (0Ā·61, 1Ā·54) | 0.62 |
Ā Placebo | 78/668 (12) | Ā | 46/403 (11) | Ā | 32/265 (12) | Ā | Ā |
Perinatal mortality | |||||||
Ā Aspirin | 41/724 (6) | 0Ā·95 (0Ā·63, 1Ā·44) | 16/445 (4) | 0Ā·56 (0Ā·31, 1Ā·03) | 25/279 (9) | 1Ā·69 (0Ā·91, 3Ā·14) | 0.014 |
Ā Placebo | 43/722 (6) | Ā | 28/439 (6) | Ā | 15/283 (5) | Ā | Ā |
Other Maternal Outcomes of Interest | |||||||
Ā Vaginal bleeding | |||||||
Ā Ā Aspirin | 12/713 (2) | 0Ā·86 (0Ā·40, 1Ā·85) | 11/437 (3) | 0Ā·91 (0Ā·41, 2Ā·05) | 1/276 (0) | 0Ā·51 (0Ā·05, 5Ā·56) | 0.64 |
Ā Ā Placebo | 14/715 (2) | Ā | 12/435 (3) | Ā | 2/280 (1) | Ā | Ā |
Antepartum hemorrhage | |||||||
Ā Aspirin | 4/721 (1) | 8Ā·95 (0Ā·48, 165Ā·94) | 4/442 (1) | 8Ā·86 (0Ā·48, 164Ā·04) | 0/279 (0) | 1Ā·01 (0Ā·02, 50Ā·76) | ā |
Ā Placebo | 0/717 (0) | Ā | 0/435 (0) | Ā | 0/282 (0) | Ā | Ā |
Postpartum hemorrhage | |||||||
Ā Aspirin | 6/724 (1) | 2Ā·99 (0Ā·61, 14Ā·77) | 2/445 (0) | 4Ā·93 (0Ā·24, 102Ā·46) | 4/279 (1) | 2Ā·03 (0Ā·37, 10Ā·99) | ā |
Ā Placebo | 2/722 (0) | Ā | 0/439 (0) | Ā | 2/283 (0) | Ā | Ā |
Maternal mortality through 42Ā days | |||||||
Ā Aspirin | 0/724 (0) | 0Ā·33 (0Ā·02, 8Ā·15) | 0/445 (0) | 0Ā·33 (0Ā·02, 8Ā·05) | 0/279 (0) | 1Ā·01 (0Ā·02, 50Ā·94) | ā |
Ā Placebo | 1/722 (0) | Ā | 1/439 (0) | Ā | 0/283 (0) | Ā | Ā |
Preterm and hypertensive disorders | |||||||
Aspirin | 1/724 (0) | 2Ā·99 (0Ā·12, 73Ā·32) | 0/445 (0) | 0Ā·99 (0Ā·02, 49Ā·61) | 1/279 (0) | 3Ā·04 (0Ā·12, 74Ā·38) | ā |
Placebo | 0/722 (0) | Ā | 0/439 (0) | Ā | 0/283 (0) | Ā | Ā |
Other Fetal Outcomes of Interest | |||||||
Ā Pretermā<ā34Ā weeks of pregnancy | |||||||
Ā Ā Aspirin | 30/724 (4) | 0Ā·88 (0Ā·54, 1Ā·42) | 15/445 (3) | 0Ā·74 (0Ā·38, 1Ā·43) | 15/279 (5) | 1Ā·09 (0Ā·53, 2Ā·21) | 0.40 |
Ā Ā Placebo | 34/722 (5) | Ā | 20/439 (5) | Ā | 14/283 (5) | Ā | Ā |
Birth weightā<ā2500Ā g | |||||||
Ā Aspirin | 76/715(11) | 0Ā·94 (0Ā·70, 1Ā·27) | 37/439 (8) | 0Ā·91 (0Ā·59, 1Ā·39) | 39/276 (14) | 0Ā·98 (0Ā·65, 1Ā·47) | 0.69 |
Ā Placebo | 80/708 (11) | Ā | 40/432 (9) | Ā | 40/276 (15) | Ā | Ā |
Birth weightā<ā1500Ā g | |||||||
Ā Aspirin | 9/715 (1) | 0Ā·69 (0Ā·29, 1Ā·59) | 1/439 (0) | 0Ā·10 (0Ā·01, 0Ā·77) | 8/276 (3) | 2Ā·67 (0Ā·71, 9Ā·95) | 0.007 |
Ā Placebo | 13/708 (2) | Ā | 10/432 (2) | Ā | 3/276 (1) | Ā | Ā |
Stillbirth | |||||||
Ā Aspirin | 14/718 (2) | 0Ā·87 (0Ā·43, 1Ā·76) | 8/442 (2) | 0Ā·87 (0Ā·34, 2Ā·23) | 6/276 (2) | 0Ā·87 (0Ā·30, 2Ā·55) | 0.99 |
Ā Placebo | 16/712 (2) | Ā | 9/432 (2) | Ā | 7/280 (3) | Ā | Ā |
Malaria in late pregnancy (26ā30Ā weeks) | |||||||
Ā Aspirin | 92/296 (31) | 1Ā·13 (0Ā·88, 1Ā·45) | 42/177 (24) | 1Ā·42 (0Ā·93, 2Ā·15) | 50/119 (42) | 0Ā·94 (0Ā·70, 1Ā·26) | 0.15 |
Ā Placebo | 83/301 (28) | Ā | 31/185 (17) | Ā | 52/116 (45) | Ā | Ā |